CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.
about
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
CD19 CAR-T cell therapy for re ...... ties and long-term efficacies.
@en
CD19 CAR-T cell therapy for re ...... ties and long-term efficacies.
@nl
type
label
CD19 CAR-T cell therapy for re ...... ties and long-term efficacies.
@en
CD19 CAR-T cell therapy for re ...... ties and long-term efficacies.
@nl
prefLabel
CD19 CAR-T cell therapy for re ...... ties and long-term efficacies.
@en
CD19 CAR-T cell therapy for re ...... ties and long-term efficacies.
@nl
P2860
P1476
CD19 CAR-T cell therapy for re ...... ities and long-term efficacies
@en
P2093
Li-Na Zhang
Yongping Song
P2860
P2888
P356
10.1186/S13045-018-0593-5
P50
P577
2018-03-15T00:00:00Z
P6179
1101538585